ZUG, Switzerland, October 11 /PRNewswire/ -- The young Swiss biotech enterprise AMVAC AG has gained reinforcement from
Prof. Michel Klein, one of the world's most renowned vaccine specialists.
Prof. Klein, who was formerly Vice President of Science & Technology of the
Aventis-Pasteur Group, will immediately assume directorship of the scientific
sector of vaccine development at AMVAC AG. This distinguished vaccinologist
has access to an outstanding network across one of the greatest growth
markets and will make a critical contribution in AMVAC AG's product research
and development. Along with the vaccine against bacterial vaginosis already
approved in Hungary, Klein is focusing on the further development of a
vaccine against prostate enlargement, for which the performance of a clinical
phase III study has been approved. In addition, AMVAC AG is preparing new
projects for indications unnamed until now. Official statements on more new
projects in the pharmaceutical industry will be released in the coming weeks.
Melinda Karpati, CEO of AMVAC, AG says, "Being able to win Prof. Michel
Klein is a great success for us and affirms not only AMVAC AG's executive?
direction, but also the continued recognition that we have come to know on
the part of experienced experts in the field of vaccine development. His
global network and the tremendous experience that Prof. Michel Klein brings
to AMVAC AG will help us develop novel prophylactic and immunotherapeutic
products in the pharmaceutical industry. Our new CSO's 40-year career has
included numerous scientific publications, distinctions and groundbreaking
vaccine developments. He has developed the five-component acellular pertussis
vaccine currently on the market, brought vaccines against PIV-3, RSV and flu
to phase I/II trials, launched the cancer vaccine program of Aventis-Pasteur
and performed more than 40 trials with several prototypes of prophylactic and
therapeutic HIV vaccines in collaboration with the NIH, WRAIR, Eurovac and
the ANRS. He is the author of more than 350 patents in the fields of
vaccinology, immunology, infectious diseases and biotechnology.
About AMVAC AG
AMVAC AG is a young biopharmaceutical company based in Switzerland that
is concentrating in the high-yield pharmaceutical industry on an especially
high-growth market segment. An average annual growth rate of 13% is forecast
until 2010 for the vaccines market, compared with 6% for pharmaceuticals in
general. AMVAC products are further characterized by meeting unfulfilled
therapy requirements in the fields of urology and gynecology. AMVAC has to
date licensed and further developed two advanced immunotherapeutic drugs with
gold standard potential. Further products are in the planning stage.
Contact:
AMVAC AG
Ariane Meynert
Metallstrasse 4
6300 Zug
Switzerland
Phone: +41-41-725-32-30
Fax: +41-41-725-32-33
Mobile: +41-79-793-34-19 / +49-172-775-92-12
E-Mail:meynert@amvac.ch
AMVAG AG
